A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
p53 (TP53, Tumor Protein p53) Gene Mutation Analysis Bookmark and Share

p53 (TP53, Tumor Protein p53) Gene Mutation Analysis

Li-Fraumeni Syndrome

Germline (heritable) mutations in the p53 gene1 predispose individuals to various tumors (early onset sarcomas and breast cancer, brain tumors, adrenal cortical carcinomas, and leukemias) associated with Li-Fraumeni syndrome 2,3. Identification of p53 gene mutations in cancer patients from Li-Fraumeni syndrome or Li-Fraumeni syndrome-like4 families may permit identification of individuals at high risk for cancer in these families.

To open a printable assay summary in a new window, click the link below.

Please submit the Test Request Form (TRF) and the Cancer Patient Information Form  when ordering this test.

References
1. Malkin, D. et al. (1990). Science 250:1233-1238.
2. Li, F. P. et al. (1988). Cancer Res. 48:5358-5362.
3. Garber, J. E. et al. (1991). Cancer Res. 51:6094-6097.
4. Birch, J. M. et al. (1994). Cancer Res. 54:1298-1304.

 

p53 (TP53, Tumor Protein p53) Gene Mutation Analysis

p53 (TP53, Tumor Protein p53) Gene Mutation Analysis

Li-Fraumeni Syndrome

Germline (heritable) mutations in the p53 gene1 predispose individuals to various tumors (early onset sarcomas and breast cancer, brain tumors, adrenal cortical carcinomas, and leukemias) associated with Li-Fraumeni syndrome 2,3. Identification of p53 gene mutations in cancer patients from Li-Fraumeni syndrome or Li-Fraumeni syndrome-like4 families may permit identification of individuals at high risk for cancer in these families.

To open a printable assay summary in a new window, click the link below.

Please submit the Test Request Form (TRF) and the Cancer Patient Information Form  when ordering this test.

References
1. Malkin, D. et al. (1990). Science 250:1233-1238.
2. Li, F. P. et al. (1988). Cancer Res. 48:5358-5362.
3. Garber, J. E. et al. (1991). Cancer Res. 51:6094-6097.
4. Birch, J. M. et al. (1994). Cancer Res. 54:1298-1304.

 
CMDL Cancer Predisposition
Cancer Predisposition
 
Neuropsychiatric Diseases
Neuropsychiatric Diseases

NLGN3

NLGN4

STK9/CDKL5

MECP2
 
Pharmacogenetics/ Personalized Medicine
Pharmacogenetics/Personalized Medicine

EGFR-NGS

KRAS-NGS
 
 
Muscular Dystrophies/Cardiomyopathies
Connective Tissue Disorders
Coagulopathies